Pharmacyte Biotech notifies Nasdaq of board independence non-compliance after director death

PharmaCyte Biotech, Inc.

Board member Thomas C.K. Yuen died Feb 13, 2022; company notified Nasdaq Feb 15, 2022.
Due to his death, majority of board no longer independent, violating Nasdaq Listing Rule 5605(b)(1).
Company has automatic cure period; expects to regain compliance by appointing new independent director.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.